{"prompt": "['Product: MK-3475', '103', 'Protocol/Amendment No.: 604-09', 'An external DMC will be convened to review accumulating safety data to provide an', 'opportunity to terminate the study early if there are concerns regarding safety.', 'Treatment-level results at the interim analyses will be provided by the external unblinded', 'statistician to the DMC. The DMC will also review the unblinded efficacy results at the', 'planned interim analyses. The DMC responsibilities and review schedules will be outlined in', 'the DMC charter. The recommendation of the DMC will be communicated to the Sponsor', 'EOC and, in the event of a recommendation to halt the trial early due to safety concerns, to', 'the appropriate regulatory agencies. If the DMC recommends modifications to the design of', 'the protocol or discontinuation of the study, the EOC may be unblinded to results at the', 'treatment level in order to act on these recommendations. Participant-level unblinding to', 'support regulatory filing, should one occur before the end of the study, will be restricted to a', 'designated Sponsor/MSD team, who will have no other responsibilities associated with the', 'study.', 'The extent to which individuals are unblinded with respect to the results will be documented.', 'Additional logistical details, revisions to the above plan, and data monitoring guidance will', 'be provided in the DMC Charter.', '8.3 Hypotheses/Estimation', 'Objectives and hypotheses of the study are stated in Section 3.0.', '8.4', 'Analysis Enppoints', '8.4.1 Efficacy Enppoints', 'Primary', 'Progression-free Survival - RECIST 1.1 assessed by BICR', 'Progression-free survival is defined as the time from randomization to the first documented', 'disease progression as assessed by BICR per RECIST 1.1 modified to follow a maximum of', '10 target lesions and a maximum of 5 target lesions per organ or death due to any cause,', 'whichever occurs first. See Section 8.6.1 for definition of censoring.', 'Overall Survival', 'Overall survival is defined as the time from randomization to death due to any cause.', 'Subjects without documented death at the time of analysis will be censored at the date of', 'last known contact.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '104', 'Protocol/Amendment No.: 604-09', 'Secondary', 'Objective Response Rate - RECIST 1.1 assessed by BICR', 'Objective response rate is defined as the proportion of subjects who have a CR or a PR.', 'Responses are based on confirmed assessments by BICR per RECIST 1.1 modified to follow', 'a maximum of 10 target lesions and a maximum of 5 target lesions per organ.', 'Duration of Response - RECIST 1.1 assessed by BICR', 'For subjects who demonstrate CR or PR, DOR is defined as the time from first documented', 'evidence of CR or PR until disease progression or death due to any cause, whichever occurs', 'first. DOR will be assessed by BICR per RECIST 1.1 modified to follow a maximum of 10', 'target lesions and a maximum of 5 target lesions per organ.', '8.4.2 Safety Enppoints', 'Safety measurements are described in Section 4.2.3.3 and Section 7. Safety and tolerability', 'will be assessed by clinical review of all relevant parameters including AEs, laboratory tests,', 'and vital signs. Safety parameters to be analyzed include, but are not limited to, AEs, SAEs,', 'fatal AEs, and laboratory changes. Furthermore, specific events will be collected and', 'designated as ECIs as described in Section 7.2.3.', '8.5 Analysis Populations', '8.5.1 Efficacy Analysis Populations', 'The analyses of primary efficacy endpoints are based on the intention-to-treat (ITT)', 'population (ie, subjects will be included in the treatment group to which they are', 'randomized). Details on the approach to handling missing data are provided in Section 8.6.', '8.5.2 Safety Analysis Populations', 'The All Subjects as Treated (ASaT) population will be used for the analysis of safety data in', 'this study. The ASaT population consists of all randomized subjects who received at least', '1 dose of study treatment. Subjects will be included in the treatment group corresponding to', 'the study treatment they actually received. For most subjects, this will be the treatment group', 'to which they are randomized. Subjects who take incorrect study treatment for the entire', 'treatment period will be included in the treatment group corresponding to the study treatment', 'actually received. Any subject who receives the incorrect study medication for 1 cycle, but', 'receives the correct treatment for all other cycles will be analyzed according to the correct', 'treatment group and a narrative will be provided for any events that occur during the cycle', 'for which the subject is incorrectly dosed.', 'At least 1 laboratory or vital sign measurement obtained subsequent to at least 1 dose of', 'study treatment is required for inclusion in the analysis of each specific parameter. To assess', 'change from baseline, a baseline measurement is also required.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}